Practical experience and outcomes of implementation of multiplatform molecular profiling in routine clinical practice for patients with rare or refractory cancer at Parisian hospitals


Marc Bollet, Alain Toledano, Hanah Lamallem, Lionel Vedrine, Judith Didi-Coulybaly, Kenneth Russell, Olivier Lefevre, Andreas Voss, David Khayat


Early outcome data describing the use of comprehensive multiplatform tumor profiling (MP) in routine clinical practice has been encouraging. MP can provide treatment options which may not have been otherwise considered for patients with rare cancers or in whom standard of care options have been tested and failed. The feasibility and application of this multiplatform approach in France has not yet been tested.

Download Publication